To prevent extensive outbreaks, asymptomatic testing at community-based facilities is included.
As anti-virus limitations are loosened, regular testing for COVID-19, flu, and RSV is critical for staying safe. Because of Seegene’s 20 years of experience, PCR tests will be reasonably priced.
“We pledge our full support to countries that join Seegene’s fight to ensure a safe return to normalcy.”/PRNewswire/ — SEOUL, South Korea, May 25th, 2022 — Seegene Inc. South Korea’s top molecular diagnostics (MDx) company, announced today a global campaign for preventive and routine PCR testing to keep people safe and healthy in the COVID-19 age.
The program, according to Dr. Jong-Yoon Chun, CEO of Seegene, is designed to help people easily return to normal while also contributing to the overall efforts to end COVID-19 and prevent future outbreaks.
As governments around the world remove social distance restrictions and eliminate mask mandates, there have been reports of an increase in influenza and common colds that were not present during the two-year outbreak. Experts are also concerned that because governments no longer conduct free PCR testing, potentially harmful mutations may go unnoticed. Individuals must now monitor their health on their own dime in order to stay safe.
asymptomatic testing for early virus identification, according to a Seegene study named “In-life PCR.” Syndromic respiratory testing will become more available when anti-virus restrictions are lifted, and PCR test accessibility will improve as prices fall.
Asymptomatic testing done ahead of time. Infected patients with weak or no symptoms can be detected using PCR assays. According to a research conducted by the CDC in the United States, asymptomatic or presymptomatic people account for almost 60% of all COVID-19 transmission. Regular symptomatic testing, with or without a doctor’s prescription, is expected to stop the spread of illnesses in public places like schools, churches, and nursing homes, and enable a safe return to regular life.
Respiratory syndromic testing Syndromic testing is critical for understanding which virus is causing a person’s symptoms and what therapy options are available. Seegene will offer the AllplexTM FluA/FluB/RSV SARS-CoV-2 Assay, that can identify SARS-CoV-2 (through the N, RdRP, and S genes), influenza B and A, and RSV (B/A) all at the same time. For SARS-CoV-2, the WHO recommends evaluating at least one or two gene transcription. If additional COVID-19 variations occur, Seegene’s assay finds three to retain detection performance. Two internal controls are included in the six-target test for enhanced precision.
Access to and affordability of PCR tests has improved. PCR testing is widely accepted as being prohibitively expensive. Seegene will collaborate with hospitals and labs to make tests more accessible and promote regular testing by lowering the cost of a test to roughly $12. Seegene has been able to minimize the barrier to entry by using great multiplex technologies that leverage on the company’s 20+ years of knowledge in molecular diagnostics.
“The ‘$12 PCR testing’ campaign is likely to aid Seegene in achieving its objective of producing molecular techniques available to everyone,” Dr. Chun added. “I am confident that widespread PCR testing would be the most effective way to aid in the eradication of the COVID-19 epidemic.” Seegene will provide complete support to towns or countries who work with us to effectively track and control the outbreak.”